The latest cannabis health, science and regulatory news from the UK and Europe.
Europe’s dedicated medical cannabis education series for clinicians and industry professionals announces two autumn events — 4 November at Mainhaus, Frankfurt, and 26 November at Conway Hall, London
France’s incoming generalised medical cannabis framework has edged closer to clearing its last remaining hurdle.
Pharmacist independent prescribers accounted for 61.9% of the total items prescribed between January 2019 and May 2025.
UK imports of the medical cannabis and the range of products available to patients both doubled in 2025.
France’s medical cannabis experiment showed treatment was effective in reducing opioid use across four indications.
Ananda Pharma has taken another major step forward in bringing its flagship MRX1 CBD oral solution to market.
Curaleaf Laboratories, one of the UK’s leading manufacturers and distributors of EU-GMP medical cannabis products and Herdade das Barrocas (HDB), a Portuguese cultivator known for its cannabis genetics and cultivation expertise, […]
Despite medical cannabis being legal in the UK for almost eight years, many patients remain hesitant or unsure about whether it is right for them. While awareness of the legality […]
We take a closer look at the data behind medical cannabis prescribing to examine what it can reliably show us.
Two years on from the legalisation of medical cannabis in Ukraine, patients have received the first legal prescriptions for cannabis-based medicines.
Exilby® has received market authorisation in Germany and Austria, with UK approval expected by the end of the year.
The development puts VER-01 in prime position to become the first FDA-approved cannabis-derived medicine for pain.
In a new multi-clinic survey, the majority of patients report improvements in their symptoms.
Upcoming Symposiums
Evidence-led education for clinicians, industry and patient advocates — across Europe.
See all events4 November 2026
Frankfurt · Mainhaus
26 November 2026
London · Conway Hall
